Ipsen has acquired global rights to a Foreseen Biotechnology antibody drug conjugate developed for an undisclosed cancer target. This is Ipsen’s second ADC deal in three months, following its acquisition of rights to a ROR1-targeting ADC from Sutro Biophrama.
The post Ipsen Turns to China-Based Biotech to Get Another ADC Cancer Drug appeared first on MedCity News.
Related Articles
Links
Hatch Waxman turns 40. FDA: Integrating RCT into routine clinical practice. Cost...
What Are the Challenges in Building a Consumer-Focused Diagnostic Testing Startup?
During a panel discussion at the MedCity News INVEST Digital Health Conference,...
BREAKING: FG Moves To Decriminalise Suicide Attempts
FG has moved to decriminalise suicide attempts. NewsOnline Nigeria reports that...
New XEC Covid variant: What are the symptoms and is it spreading in the UK?
The Covid-19 pandemic is constantly changing, with new variants appearing occasionally. Lately,...
Leave a comment